Transcription Factor, MITF, is a master regulator of melanocyte development, differentiation, migration and survival.
Cell reprogramming, where the epigenetic signature directing cellular identity can be erased and rewritten, demonstrates the pervasive and far-reaching importance of transcription factors in the development, maintenance and rewiring of cells. 2 In 2006, Takahashi and Yamanaka published their seminal study on cell reprogramming, showing that only four selected transcription factors were required to directly and permanently transform adult mouse fibroblasts into induced pluripotent stem (iPS) cells. 3, 4 However, reprogramming can also include the conversion of one somatic cell type to another.
In 1996, it was shown that ectopic expression of a single transcription factor, MITF, may convert fibroblasts into cells with characteristics of pigment-producing
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The case of MITF in melanocytes Carmit Levy and David E. Fisher* Cutaneous Biology Research Center; Department of Dermatology; Massachusetts General Hospital; Harvard Medical School; Boston, MA USA melanocytes. 5 Similarly, ectopic expression of MITF into Medaka embryonic stem cells drives differentiation into melanocytes. 6 Conversely loss of function mutations in MITF produce depigmentation that is different from albinism, 7 where melanocytes exist but pigment production is defective. Instead, MITF deficiency produces depigmentation due to absence of viable melanocytes. [8] [9] [10] Interestingly, besides its role in melanocyte survival/ proliferation, it is also clear that MITF transcriptionally regulates expression of numerous pigmentation genes. Thus, MITF appears to be a master regulator of melanocyte development, differentiation, migration, survival and function.
The extent and permanence of genetic, epigenetic and developmental changes emphasize the central role for lineage-specific transcription factors in imprinting a cell's lineage and identity. The study of MITF as a model lineage-restricted transcription factor both illustrates and extends our understanding of epigenetic changes and gene expression during cell development, maintenance and function.
MITF is a basic helix-loop-helix leucine zipper (bHLHzip) protein that recognizes and interacts with canonical E-box promoter/enhancer sequences as an obligate dimer. [11] [12] [13] Several related bHLHzip transcription factors are capable of heterodimerizing with MITF and binding to identical DNA sequences. The related factors TFEB, TFE3 and TFEC, together with MITF, are collectively termed the MiT family. 12 Whereas MITF expression appears to be largely restricted to certain specific cell-types, other members of the and this may simultaneously require lineage commitment or differentiation.
When analyzing current information regarding target genes of MITF, several major questions become evident. Firstly, several MITF target genes possess functions that appear contradictory or conflicting. For example, MITF can act as an anti-proliferative transcription factor by modulating p21, but can equally promote cell cycle progression by transcription of the CDK2 gene. Secondly, its targets are not uniformly responsive to MITF among different tested experimental systems. Thus, the ectopic expression of MITF in fibroblasts drove expression of melanogenic marker genes such as Tyrosinase. 5 In contrast, when Gaggioli, et al. overexpressed MITF in B16 mouse melanoma cells or human melanocytes, Tyrosinase expression remained static. However, transfection with a dominant negative form of MITF inhibits Tyrosinase expression, suggesting that MITF is required but not sufficient for Tyrosinase expression. 23 Interestingly, in reprogramming studies, only a small fraction (2%) of MITF transfected fibroblasts became melanocyte-like cells, 5 suggesting the involvement of additional unknown factors in modulating certain MITF activities. Of course additional technical differences may account for variations in experimental observations, such became one of the first MITF target genes to be identified that was not involved in pigmentation, but rather in cell survival. 15 Later, additional MITF target genes important for the proliferation and survival of melanocyte were described: the anti apoptotic factor BCL2, 16 cyclindependent kinase 2 (CDK2), 17 the cyclin dependent kinase inhibitors p21 Cip1 (CDKN1A) 18 and p16/INK4A, 19 diaphanous-related forming 1 (DIA1), 20 and the c-MET receptor tyrosine kinase. 21 A recent observation by our laboratory revealed that, upon melanocyte differentiation, MITF induces the transcription of DICER, a key RNase III endonuclease crucial to miRNA biogenesis. 22 These studies demonstrated that MITF transcriptionally upregulates DICER during cAMP induced melanocyte differentiation, causing DICER-dependent processing of the pre-miRNA-17_92 cluster, thus targeting BIM, which results in enhanced melanocyte survival. 22 Interestingly, MITF-dependent expression of TBX2 and DICER appears to occur after commitment to the melanocyte lineage 15 in the case of TBX2 or upon cAMP induced differentiation 22 in the case of DICER. Although certain MITF target genes are ubiquitously expressed (i.e., not restricted to the melanocyte lineage), their expression in melanocytes is MITF-dependent MiT family are thought to be more ubiquitously expressed.
Currently, MITF is known to regulate a number of genes of importance in differentiation and maintenance of the melanocyte lineage ( Table 1) . 1 A tissue restricted transcription factor with the ability to epigenetically transform somatic cells into melanocytes 5 and facilitate functions crucial to lineage development and survival is expected to activate both lineage-specific (A) and ubiquitously expressed genes involved in basic cell maintenance (B). [8] [9] [10] (A) MITF-activated melanocyte specific genes include those controlling differentiation, which, for melanocytes, is largely defined as pigmentation. Such genes include Tyrosinase, TYRP1, TYRP2/DCT, MART1/MLANA, SILV/ PMEL17, AIM1 and TRPM1 (reviewed in ref. 1). This subset of genes, together with its activator MITF, exhibits a lineage specific expression pattern and may be exploited as lineage markers, which aid in the diagnosis of melanocytic neoplasms, especially melanoma. 14 (B) MITF also appears to regulate the expression, in melanocytes, of genes which are also expressed in many other cell types. Among the known genes in this category are regulators of cell cycle progression, apoptosis, proliferation and survival. In 2000, TBX2 (T-box transcription factor) in MITF interactions with chromatin, although numerous details remain to be determined, including the uniformity (or variation) of these patterns among distinct subsets of MITF target genes. Chromatin modification is likely key to the regulation of MITF transcriptional activity. MITF can likely relax chromatin by recruiting the histone acetyl transferase CBP/p300 to the Tyrosinase promoter. 25, 26 It is currently unclear whether endogenous target genes other than Tyrosinase are subject to this transcriptional mechanism. It was also described that MITF recruits the SWI/SNF complex to the promoters of differentiation-related targets Tyrosinase and TRP1, but not to cell maintenance genes TBX2 and BCL2. 27, 28 This mechanism is suggested to drive selective expression of MITF target genes. SWI/SNF complexes are ATP-dependent chromatinremodeling enzymes that alter the position of nucleosomes along the chromosome and, as a consequence, affect promoter accessibility to regulatory factors. 29, 30 In their work, Keenen et al. indicate that epigenetic modulation contributes to direct expression of distinct gene classes. MITF may therefore both control and be controlled by its access to nucleosomefree stretches of target sequence. Clearly, additional studies are required to fully explain how chromatin structure affects MITF access and interactions with its targets through different developmental stages.
The map of genes expressed at a given time is crucial for maintaining normal cell function. Studies of MITF have yielded new molecular intricacies, regulatory paradoxes and a multitude of unanswered questions, illuminating the likely complexity of regulatory layers required to induce expression of the right target at the right time in the life of a cell. As greater insights are gleaned into the mechanistic underpinnings of epigenetic regulation, cellular reprogramming and lineage determination, MITF may emerge as an attractive model transcription factor and simultaneously provide valuable information of relevance to human diseases, including pathologic pigmentation patterns and melanocytic neoplasms.
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Taken together, MITF is regulating several apparently distinct biological classes of genes which may offer a unique opportunity to study the mechanisms involved in harnessing an individual transcription factor to control multiple phenotypic outcomes. One interesting case involves the transcription of CDK2 (cell cycle progression) and SILVER/ PMEL17 (differentiation/pigmentation). Although these genes reside in apparently highly distinct cellular pathways, they are thought to be regulated by the identical MITF-targeted promoter/enhancer element because of their nearly overlapping genomic location (head-to-head adjacent configuration). Whereas MITF's control of both genes appears to be melanocytespecific, the CDK2 gene is ubiquitously expressed and did not appear to require the MITF-targeted E box element when studied in non-melanocytic cells. 17 Many mechanisms regulating MITF transcriptional activity remain unknown. It seems plausible that specific checkpoints in melanocyte development and function tune MITF activation of specific genes, but the precise stimuli driving preferential transcription of specific genes have not been mapped. The "dynamic epigenetic" model 20 postulates a threshold of MITF activity in which low levels of MITF activity promote proliferation, whereas higher levels are required for terminal differentiation. 20 However, the factors regulating MITF activity, from extracellular-derived signals to molecular co-factors or chromatin modifications altering promoter accessibility, are mostly unknown.
Recent epigenetic studies may shed light on these questions. In high resolution chromatin analyses from our lab, Ozsolak et al. combined nucleosome positioning data with chromatin immunoprecipitation-chip profiles and revealed that MITF predominantly binds nucleosome-free regions, supporting the model that nucleosomes limit sequence accessibility 24 (or the transcription factor may confer nucleosome phasing by its DNA binding). These studies suggest the involvement of nucleosome positioning
